SCHEMBL2541804

SCHEMBL2541804

CCCc1cc2c(=O)c(-c3ccccn3)coc2cc1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.74
SMN1; SMN2 Q16637 5/20 0.74
NPC1 O15118 4/20 0.74
TDP1 Q9NUW8 1/20 0.74
KDM4E B2RXH2 5/20 0.67
HPGD P15428 4/20 0.67
HSD17B10 Q99714 3/20 0.67
NPSR1 Q6W5P4 2/20 0.67
TSHR P16473 1/20 0.67
ADORA2A P29274 7/20 0.62
USP2 O75604 2/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
MAPT P10636 3/20 0.42
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
ALDH1A1 P00352 4/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2545819 0.87 SMN1; SMN2 (0.68) RAB9ASMN1; SMN2NPC1TDP1KDM4E
SCHEMBL12238010 0.85 NPC1 (0.77) RAB9ASMN1; SMN2NPC1TDP1KDM4E
SCHEMBL29395943 0.83 NPC1 (0.78) RAB9ASMN1; SMN2NPC1TDP1KDM4E
SCHEMBL470778 0.83 NPC1 (0.78) RAB9ASMN1; SMN2NPC1TDP1KDM4E
SCHEMBL12238019 0.82 RAB9A (0.60) RAB9ASMN1; SMN2NPC1TDP1KDM4E
SCHEMBL5315467 0.80 KDM4E (1.00) RAB9ASMN1; SMN2NPC1TDP1KDM4E
SCHEMBL12238007 0.79 SMN1; SMN2 (0.86) RAB9ASMN1; SMN2NPC1TDP1KDM4E
SCHEMBL12238011 0.78 ADORA2A (0.64) RAB9ASMN1; SMN2NPC1TDP1KDM4E
SCHEMBL12940593 0.77 RAB9A (0.60) RAB9ASMN1; SMN2NPC1TDP1KDM4E
SCHEMBL2549638 0.76 KDM4E (0.64) RAB9ASMN1; SMN2NPC1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9408826-B2 Isoflavone anti-viral compounds Kineta, Inc. (US) 2016-08-09 US disclosed
US-9408826-B2 Isoflavone anti-viral compounds Kineta, Inc. (US) 2016-08-09 US disclosed
US-9408826-B2 Isoflavone anti-viral compounds Kineta, Inc. (US) 2016-08-09 US disclosed
EP-2560652-A2 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2013-02-27 EP disclosed
US-20110262482-A1 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 US disclosed
US-20110262482-A1 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 US disclosed
US-20110262482-A1 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 US disclosed
WO-2011133728-A2 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 WO disclosed
WO-2011133728-A2 ANTI-VIRAL COMPOUNDS Kineta, Inc. (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110262482-A1 ANTI-VIRAL COMPOUNDS MAVS, EIF2AK2, IRF3 RAB9A 812/4885SMN1; SMN2 2632/4885NPC1 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.